Etiome emerges with $50M from Flagship Pioneering and goal of preempting disease

Title

Etiome Launches With $50M Backing From Flagship Pioneering to Pioneer Preemptive Disease Medicine

Etiome has launched with $50 million in funding from Flagship Pioneering, aiming to develop medicines that intervene before diseases manifest clinically1 2.
The company focuses on creating preemptive medicines targeting serious and progressive conditions such as metabolic, neurodegenerative, autoimmune diseases, and cancers1 2.
Etiome’s foundation is its proprietary Temporal Biodynamics™ platform, which leverages multiomics data, artificial intelligence (AI), and electronic health records (EHRs) to map the evolution of disease at the molecular and cellular level1 2 3.
This approach seeks to identify key biomarkers and critical intervention windows—so-called "silent windows"—to treat or halt diseases at the earliest possible stage, potentially before symptoms appear1 2 4.
The startup originated from Flagship’s Preemptive Health and Medicine Initiative and is led by founding CEO Avak Kahvejian, Ph.D.1 3.
Etiome’s early efforts focused on metabolic dysfunction-associated steatohepatitis (MASH), developing detailed molecular timelines of disease progression1.
The company aims to redefine disease management by shifting healthcare from reactive to proactive, leveraging predictive insights to develop stage-specific, targeted therapeutics2 3.
With significant initial funding and a focus on unmet medical needs, Etiome is positioned as a potential innovator in the field of preventive and precision medicine2 3 4.